Top left, engagement of the peptide with the receptor ECD releases ECD constraints on the transmembrane domain promoting outward movements of TM1, TM6 and TM7 by peptide
Overall, adverse effects account for approximately a 10% discontinuation rate of the medication
[9] He also proposed that such incretins could be used as a treatment for diabetes mellitus
The growing pharmaceutical interest in this compound stems from its simultaneous targeting of multiple pathological processes, including oxidative stress, aberrant cellular proliferation, and inflammatory cascades, making it particularly valuable for complex disease conditions such as cancer, cardiovascular diseases, and cerebrovascular disorders including cerebral ischemia [2]
And the extended titration approach, maintaining each step for six weeks instead of four, dramatically improves tolerability for sensitive individuals